Reuters logo
BRIEF-Transgene SA says first results from Phase 2 trial could be expected from end of 2017
2017年3月13日 / 晚上6点20分 / 6 个月前

BRIEF-Transgene SA says first results from Phase 2 trial could be expected from end of 2017

March 13 (Reuters) - Transgene SA :

* First patient dosed in Phase 2 trial evaluating Transgene’s TG4010 in combination with Opdivo(nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (NSCLC)

* First results from Phase 2 trial could be expected from end of 2017 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below